EpiThany, Merck KGaA, Pfizer to evaluate combination of avelumab and EP-101 STEMVAC in breast cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

EpiThany today announced that they have entered into a collaboration agreement with Merck KGaA, Darmstadt, Germany, and Pfizer to evaluate avelumab*, a human anti-PD-L1 antibody, and EP-101 STEMVAC, a multi-antigen, polyepitope vaccine, in a phase II trial in women with breast cancer.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

After reading “Breast Cancer Mortality Continues Three-Decade Decline, but Steeper Increases for Women Under 50 & AAPI Women of All Ages,” it is evident that while overall progress is being made in the fight against cancer, concerning disparities remain—particularly within the Native Hawaiian and Pacific Islander (NHPI) communities. 

Login